# Moderna, Inc. (MRNA) FY2026 Q2 Balance Sheet

- Company: Moderna, Inc. (MRNA)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-31, accession number 0001682852-26-000150
- Page: https://plicit.ai/financials/mrna/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/mrna-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 10,961,000,000 US dollars
- **Current assets**: 5,815,000,000 US dollars
- **Non-current assets**: 5,146,000,000 US dollars
- **Liabilities**: 4,200,000,000 US dollars
- **Current liabilities**: 2,534,000,000 US dollars
- **Non-current liabilities**: 1,666,000,000 US dollars
- **Equity**: 6,761,000,000 US dollars
- **Investments**: 3,415,000,000 US dollars
- **Cash and cash equivalents**: 1,723,000,000 US dollars
- **Prepaid expenses and other current assets**: 380,000,000 US dollars
- **Inventory**: 280,000,000 US dollars
- **Accounts receivable, net**: 17,000,000 US dollars
- **Property, plant and equipment, net**: 2,059,000,000 US dollars
- **Investments, non-current**: 1,772,000,000 US dollars
- **Right-of-use assets, operating leases**: 697,000,000 US dollars
- **Other non-current assets**: 618,000,000 US dollars
- **Accrued liabilities**: 1,909,000,000 US dollars
- **Deferred revenue**: 295,000,000 US dollars
- **Accounts payable**: 167,000,000 US dollars
- **Other current liabilities**: 163,000,000 US dollars
- **Operating lease liabilities, non-current**: 638,000,000 US dollars
- **Long-term debt**: 591,000,000 US dollars
- **Other non-current liabilities**: 284,000,000 US dollars
- **Deferred revenue, non-current**: 147,000,000 US dollars
- **Financing lease liabilities, non-current**: 6,000,000 US dollars
- **Retained earnings**: 5,098,000,000 US dollars
- **Additional paid-in capital**: 1,644,000,000 US dollars
- **Accumulated other comprehensive income**: 19,000,000 US dollars
- **Preferred stock, par value $0.0001; 162 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued or outstanding at June 30, 2026 and December 31, 2025**: 0 US dollars
- **Common stock, par value $0.0001; 1,600 shares authorized as of June 30, 2026 and December 31, 2025; 399 and 394 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively**: 0 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.